Bryan A. Roecklein

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

MedPointe, Inc. develops, markets, and sells therapeutics. The company's products include respiratory, allergy, central nervous system, cough/cold, and pediatric products. The company was founded by James S. Burns and Anthony H. Wild in 2001 and is headquartered in Somerset, NJ.

Meda Pharmaceuticals, Inc. manufactures and develops drugs and pharmaceuticals. The firm specializes in respiratory, allergy, central nervous system, and cough-cold products. Its products include Aerospan, Anadrol-50, Astelin, Astepro, BiferaRx, Butisol Sodium, Cesame, Colyte, Cortifoam, Demadex, Depen, Dipentum, Edlua, Rowasa, Optivar, Soma and Levsin. The company was founded in 2001 and is headquartered in Somerset, NJ.